GlassScriptPhysician profile
Stephen A Bloom
NPI 1972552552
$4,530.57
in general payments reported to CMS, 2019-2025
35 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,105 · 2020: $84.01 · 2021: $202 · 2022: $1,307 · 2023: $739 · 2024: $566 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,814 · Education: $18.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,813.90 |
| Education | $18.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $700.30 | 2019-2025 | |
| Amgen INC. | $572.04 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $492.78 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $323.28 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $309.79 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $306.95 | 2019-2024 | Watchman Flx |
| Irhythm Technologies, INC. | $214.88 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Astrazeneca Pharmaceuticals LP | $213.37 | 2021-2025 | Wainua |
| Cleerly, INC. | $172.66 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.48 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $137.62 | 2021-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $130.07 | 2019-2022 | |
| Daiichi Sankyo INC. | $96.47 | 2019 | |
| Novo Nordisk INC | $91.36 | 2022-2025 | Wegovy, Ozempic |
| Regeneron Healthcare Solutions, INC. | $83.38 | 2019-2024 | Evkeeza |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $80.63 | 2022-2023 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $56.99 | 2019-2025 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $50.15 | 2019-2021 | |
| Philips North America LLC | $48.34 | 2022-2023 | |
| Lemaitre Vascular, INC. | $44.00 | 2024 | Restoreflow |
| Abbott Laboratories | $41.46 | 2023-2024 | Cardiomems, Mitraclip |
| Amarin Pharma, INC. | $39.65 | 2019-2021 | |
| Recor Medical INC | $29.38 | 2025 | Paradise Ultrasound Renal Denervation System |
| Bayer Healthcare Pharmaceuticals INC. | $27.67 | 2021-2025 | |
| Akcea Therapeutics, INC. | $27.11 | 2019 | |
| Bolton Medical INC | $23.27 | 2019 | |
| Medtronic Vascular, INC. | $21.66 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $16.77 | 2023 | Arcalyst |
| Heartflow, INC. | $14.01 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $13.94 | 2024 | Arcalyst |
| Cvrx, INC. | $10.11 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$299,989.02 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.